|
Treatment group |
TOF ratio at or before extubation, n (%) |
Sugammadex 4.0 mg/kg
(n=50a) |
Neostigmine 50 μg/kg
(n=43a) |
≥0.9 |
48 (96.0)b |
17 (39.5)b,c |
>0.8 to <0.9 |
1 (2.0) |
6 (14.0) |
>0.7 to ≤0.8 |
0 (0.0) |
5 (11.6) |
>0.6 to ≤0.7 |
0 (0.0) |
5 (11.6) |
≤0.6 |
1 (2.0) |
10 (23.3) |
aPatients with data available: In total, three patients (one sugammadex and two
neostigmine) were excluded from the table because monitoring was stopped before
extubation due to the patient moving or waking up. The last recorded TOF
ratios were 0.8 in the sugammadex patient and 0.5 and 0.6, respectively, in the
neostigmine patients, but it cannot be discounted that these patients would have
recovered to a TOF ratio of ≥0.9 by the time of extubation. In addition, one neostigmine
patient was not included because the TOF trace was considered to be
unreliable; bIncludes seven patients in the sugammadex group and five patients
in the neostigmine group in whom the monitor was switched off before extubation
because the patient was already awake or moving but who had reached a TOF
ratio of ≥0.9; cFisher’s exact test, P=<0.0001 for sugammadex versus neostigmine |
